reference/2436994

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2436994

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article
endingPage	3250
issn	0959-8049
issueIdentifier	18
pageRange	3243-3250
publicationName	European journal of cancer (Oxford, England : 1990)
startingPage	3243
bibliographicCitation	Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 2010 Dec;46(18):3243–50. doi: 10.1016/j.ejca.2010.08.001. PMID: 20822897.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1590-485X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9bcd97fd1292ae4a518a6aea4897b94f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7142dbb63fcd4a84581fa26da6657825 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f1c88f740f477d113988d91e60e9b89 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a84864b4caead3ff922466ba7d5c6db8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1fae260b65f185d9d8c6d4d4a93ecb28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b878d0a142431e5d904b6be29daea3bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81b499fb13408507abe6025e882014b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d008a1b6c4bec4f0715c421387f7c5ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_44d057d2be3b4386a0e96fc3bcc50f45 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7888421721bde6aad68678c0894d6087 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89d12999a8848f07566dc1644040b12d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c93503e370200a46f83feb06994404c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c39bc1156dec98b99130c2afd2e0acb0
date	201012
identifier	https://pubmed.ncbi.nlm.nih.gov/20822897 https://doi.org/10.1016/j.ejca.2010.08.001
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1697 https://portal.issn.org/resource/ISSN/0959-8049
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
discusses	http://id.nlm.nih.gov/mesh/M0018169 http://id.nlm.nih.gov/mesh/M0273114 http://id.nlm.nih.gov/mesh/M0001483
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D011687Q000009 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D009369Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000077546 http://id.nlm.nih.gov/mesh/D009325Q000139 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D014839Q000139 http://id.nlm.nih.gov/mesh/D008659Q000139 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011687Q000008 http://id.nlm.nih.gov/mesh/D056486Q000209 http://id.nlm.nih.gov/mesh/D020714
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID160355 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7998 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8349 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57741935 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3c1afdc4df89db197401645db6998055 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127565238

Total number of triples: 66.